Menu
RegimensEvidenceLearnHealthTrainingQualityAboutFAQ
Take the quizES

Everstack Evidence

DLast reviewed

Metformin and the TAME trial

A proposed trial design; outcome data in non-diabetic people are not yet available.

Published Sources checked 1 sourceEverstack research teamHow we work

Human fibroblasts, fluorescence: mitochondria in red, nuclei in blue, nanoparticles in green
Human fibroblasts, fluorescence: mitochondria in red, nuclei in blue, nanoparticles in green. Image: Matteo Battaglini, CC BY 4.0

Editorial section. Research summaries are not product claims and contain no product links or offers. A summary is never proof that any product works.

The question
Why do researchers want to test metformin as an aging drug?
Study design
Perspective paper (2016) laying out the rationale and design of TAME (Targeting Aging with Metformin). [1]
What they found
The authors argue that a trial using a composite of age-related diseases as its endpoint could establish aging itself as a target for drug development, using metformin as the first test case. [1]
Limitations
A proposal, not results. Metformin is a prescription drug.
What this does not mean
There is no proof yet that metformin slows aging in people without diabetes.
Sources
  1. Barzilai N et al. Cell Metab. 2016;23(6):1060-1065. doi.org/10.1016/j.cmet.2016.05.011

Where it is discussed on podcasts

Verified episodes. Hosts and guests do not endorse Everstack. Podcast index

Spot an error? Email hello@everstackhealth.com and we will correct it within 48 hours.